Characteristics of one HVPG and two follow-up validation
cohorts
A total of 1,304 cirrhotic patients were included from three cohorts
(i.e., international HVPG cohort, international follow-up cohort, and
carvedilol-treating cohort, sFigure 3), which were employed to validate
the diagnostic performance to predict cumulative decompensation events
and to guide carvedilol therapy by using the novel CSPH risk model,
respectively. The mean (±standard deviation [SD]) ages were 55.6
(11.3), 54.8 (11.4), 52.8 (10.1) years, while the LSM values were 16.9,
18.7, and 19.4 kPa, and 58.9%, 75.7%, and 100% were viral
hepatitis-related cirrhosis in the international HVPG cohort,
international follow-up cohort, and carvedilol-treating cohort,
respectively (Tables 1 and sTable 3). Notably, the median follow-up
durations between the international follow-up cohort and the
carvedilol-treating cohort were similar (39.0 [25.2-55.2] months vs
38.0 [23.0-44.0] months) (Tables 1 and sTable 3).